Kura Oncology Inc

NASDAQ:KURA   3:59:50 PM EDT
19.02
+0.04 (+0.21%)
Products

Kura Oncology Doses First Patient In Phase 1B Expansion Cohorts With Menin Inhibitor Ko-539

Published: 06/24/2021 12:42 GMT
Kura Oncology Inc (KURA) - Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts With Menin Inhibitor Ko-539.
Kura Oncology Inc - at Least 12 Patients to Be Enrolled in Each of Two Phase 1b Expansion Cohorts: a 200 Mg Dose Cohort and a 600 Mg Dose Cohort -.
Kura Oncology Inc - Phase 1b Expansion Cohorts Designed to Enable Refinement of Recommended Phase 2 Dose.